Valuation: Genomma Lab Internacional, S.A.B. de C.V.

Market Cap 14.39B 822M 718M 663M 611M 1.15B 79.13B 1.18B 7.92B 3.12B 38.76B 3.09B 3.02B 133B P/E 2026 *
7.14x
P/E 2027 * 6.65x
Enterprise Value 18.26B 1.04B 911M 840M 775M 1.46B 100B 1.49B 10.05B 3.95B 49.15B 3.91B 3.83B 169B EV / Sales 2026 *
1x
EV / Sales 2027 * 0.91x
Free-Float
68.95%
Yield 2026 *
5.43%
Yield 2027 * 7.44%
04-23 Genomma Lab Internacional, S.A.B. de C.V., Q1 2026 Earnings Call, Apr 23, 2026
04-23 Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
02-26 Genomma Lab Internacional, S.A.B. de C.V., Q4 2025 Earnings Call, Feb 26, 2026
02-25 Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
12-09 Genomma Lab Internacional Announces Fourteenth Dividend Payment, Payable on December 23, 2025 CI
25-10-23 Genomma Lab Internacional, S.A.B. de C.V., Q3 2025 Earnings Call, Oct 23, 2025
25-10-21 Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-07-24 Genomma Lab Internacional, S.A.B. de C.V., Q2 2025 Earnings Call, Jul 24, 2025
25-07-23 Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-06-24 Genomma Lab Internacional, S.A.B. De C.V. Announces Twelfth Quarterly Dividend Payment, Payable on July 1, 2025 CI
25-06-04 Genomma Lab Successfully Issued the Lab 25 and Lab 25-2 Unsecured Bonds for A Total Amount of $1.2 Billion Pesos, Which Will Be Used to Prepay Liabilities, Including the Full Early Amortization of the Lab 23 Bond CI
25-05-01 Genomma Lab Internacional, S.A.B. de C.V., Q1 2025 Earnings Call, May 02, 2025
25-04-30 Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
1 day+2.77%
1 week+2.77%
Current month+2.77%
1 month+2.38%
3 months-20.37%
6 months-17.30%
Current year-18.87%
1 week 0.86
Extreme 0.86
0.86
1 month 0.84
Extreme 0.8368
0.86
Current year 0.84
Extreme 0.8368
1.08
1 year 0.84
Extreme 0.8368
1.17
3 years 0.73
Extreme 0.7265
1.43
5 years 0.67
Extreme 0.67
1.43
10 years 0.51
Extreme 0.5138
2
Manager TitleAgeSince
Chief Executive Officer - 2023-04-11
Director of Finance/CFO - 2015-11-30
Investor Relations Contact - 2019-09-30
Director TitleAgeSince
Director/Board Member - -
Director/Board Member - 2016-12-31
Chairman - 1996-10-29
Change 5-day change 1-year change 3-year change Capi.($)
+2.77%+2.77% - - 822M
+0.85%-0.80%+52.79%+161.33% 1,051B
+1.23%-1.53%+54.58%+59.08% 609B
+0.04%+2.58%+34.47%+86.33% 450B
+0.78%-0.71%+29.28%+24.10% 330B
+1.41%+0.58%+35.44%+40.67% 284B
-0.27%-1.87%+22.34%+22.51% 263B
-1.76%+2.37%-20.43%-38.00% 223B
-1.42%+0.80%+24.27%+57.50% 198B
-1.48%+3.43%+24.08%+71.67% 167B
Average +0.22%+0.54%+28.54%+53.91% 397.23B
Weighted average by Cap. +0.37%+0.02%+37.51%+79.63%

Financials

2026 *2027 *
Net sales 18.26B 1.04B 911M 841M 775M 1.46B 100B 1.49B 10.05B 3.95B 49.16B 3.91B 3.83B 169B 19.58B 1.12B 977M 901M 831M 1.57B 108B 1.6B 10.77B 4.24B 52.72B 4.2B 4.11B 181B
Net income 2.05B 117M 102M 94.17M 86.8M 164M 11.25B 167M 1.13B 443M 5.51B 439M 429M 18.96B 2.25B 128M 112M 104M 95.51M 180M 12.37B 184M 1.24B 487M 6.06B 483M 472M 20.86B
Net Debt 3.86B 220M 193M 178M 164M 309M 21.23B 316M 2.12B 836M 10.4B 828M 810M 35.79B 3.46B 198M 173M 159M 147M 277M 19.04B 283M 1.91B 750M 9.33B 743M 726M 32.11B
Logo Genomma Lab Internacional, S.A.B. de C.V.
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
Employees
1,643
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
14.76MXN
Average target price
24.00MXN
Spread / Average Target
+62.60%

Quarterly revenue - Rate of surprise